SEAL Therapeutics is developing its proprietary SEAL technology as a potential gene therapy for laminin-α2 deficient congenital muscular dystrophy (LAMA2 MD), a severe and progressive neuromuscular disease affecting children from birth. SEAL Therapeutics aims to team-up with and support a qualified pharma partner with experience in advanced gene therapy technologies for clinical development to ultimately make this innovative treatment approach available to patients.